Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 421,000 | 174,000 | 213,584 | 132,944 | 307,584 |
| Marketable Securities | 259,000 | 436,000 | 363,625 | 614,818 | 432,612 |
| Receivables | 158,000 | 122,000 | 73,390 | 40,445 | 28,432 |
| Inventories | 52,000 | 45,000 | 33,969 | 26,766 | 16,231 |
| TOTAL | $951,000 | $817,000 | $732,184 | $883,899 | $856,604 |
| Non-Current Assets | |||||
| PPE Net | 244,000 | 266,000 | 290,566 | 259,726 | 141,247 |
| Investments And Advances | 57,000 | 135,000 | 199,901 | 148,970 | 293,858 |
| Intangibles | 220,000 | 222,000 | 210,677 | 204,511 | 175,194 |
| Other Non-Current Assets | 60,000 | 63,000 | 57,685 | 48,338 | 55,494 |
| TOTAL | $581,000 | $686,000 | $758,829 | $661,545 | $665,793 |
| Total Assets | $1,532,000 | $1,503,000 | $1,491,013 | $1,545,444 | $1,522,397 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 31,000 | 39,000 | 42,114 | 43,274 | 17,138 |
| Accrued Expenses | 265,000 | 241,000 | 196,486 | 204,678 | 145,555 |
| Other current liabilities | 76,000 | 54,000 | 29,242 | 1,479 | 7,609 |
| TOTAL | $384,000 | $344,000 | $280,437 | $261,210 | $181,368 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,198,000 | 874,000 | 905,104 | 900,073 | 385,162 |
| TOTAL | $1,228,000 | $904,000 | $935,162 | $931,740 | $418,468 |
| Total Liabilities | $1,612,000 | $1,248,000 | $1,215,599 | $1,192,950 | $599,836 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 96,630 | 92,501 | 82,336 | 70,217 | 69,385 |
| Common Shares | N/A | N/A | 82 | 70 | 69 |
| Retained earnings | -4,532,000 | -3,957,000 | -3,387,661 | -2,781,022 | -2,073,601 |
| Other shareholders' equity | 9,000 | 3,000 | 647 | -6,573 | -1,404 |
| TOTAL | $-80,000 | $255,000 | $275,414 | $352,494 | $922,561 |
| Total Liabilities And Equity | $1,532,000 | $1,503,000 | $1,491,013 | $1,545,444 | $1,522,397 |